Differential interactions of "prosexual" drugs with 5-hydroxytryptamine1A and alpha 2-adrenergic receptors.
L L Kwong, E R Smith, J M Davidson, S J Peroutka
Behavioral neuroscience October 1, 1986 DOI: 10.1037//0735-7044.100.5.664 via PubMed
Summary
AI-generated from the abstractThree prosexual drugs—8-OH-DPAT, 5-methoxy-dimethyltryptamine, and RDS-127—showed strong potential as selective inhibitors of 5-HT1A receptor binding, suggesting they may enhance seminal emissions and ejaculations. In contrast, yohimbine, imiloxan, and idazoxan primarily affected alpha 2-adrenergic receptors. The study analyzed interactions using radioligand binding techniques on rat brain membranes, providing insights into the mechanisms underlying sexual behavior. Understanding these interactions could pave the way for new treatments addressing sexual dysfunction.
Study at a glance
| Characteristics | Radioligand binding study Peer reviewed |
|---|---|
| Population | Rat brain membranes |
| Interventions | 8-OH-DPAT 5-methoxy-dimethyltryptamine RDS-127 yohimbine imiloxan idazoxan |
| Citations | 38 |
| Key finding | Drugs that facilitate ejaculation selectively bind to 5-HT1A receptors, while drugs that increase sexual arousal selectively bind to alpha 2-adrenergic receptors. |
Abstract
Radioligand binding studies were used to analyze the interactions of six "prosexual" drugs with 5-hydroxytryptamine1A (5-HT1A) and alpha 2-adrenergic receptors in rat brain membranes. Three drugs that facilitate seminal emissions and/or ejaculations [8-hydroxy-2-n-propylaminotetralin (8-OH-DPAT), 5-methoxy-dimethyltryptamine, and RDS-127] are potent and selective inhibitors of [3H]8-OH-DPAT binding to 5-HT1A receptors. By contrast, three drugs with primary sexual arousal effects (yohimbine, imiloxan, and idazoxan), are potent agents at alpha 2-adrenergic receptors labeled by [3H]yohimbine. These data suggest that radioligand binding analysis of prosexual agents may elucidate the pathophysiology of sexual behavior.